Results 221 to 230 of about 63,830 (268)
Some of the next articles are maybe not open access.

Endothelins and asthma

Life Sciences, 1999
In the decade since endothelin-1 (ET-1) and related endogenous peptides were first identified as vascular endothelium-derived spasmogens, with potential pathophysiological roles in vascular diseases, there has been a significant accumulation of evidence pointing to mediator roles in obstructive respiratory diseases such as asthma.
R G, Goldie, P J, Henry
openaire   +2 more sources

Endothelin, endothelin receptors, and endothelin antagonists

Current Opinion in Nephrology and Hypertension, 1994
Endothelin is a peptide with potent biologic effects in vascular and nonvascular cells. Its effects are mediated by two receptors, ETA and ETB, and possibly also by a third receptor, ETC. In vascular smooth muscle cells, endothelin causes profound contraction and also has proliferative effects, mainly through activation of ETA but also through ETB ...
openaire   +1 more source

Endothelin XVI

Canadian Journal of Physiology and Pharmacology, 2020
Although 31 years have passed since the discovery of endothelin, that pioneering report, and the subsequent flood of influential studies elucidating its molecular and clinical details, have since paved the way for thousands of publications. They showed the promise of endothelin and the vast amount of work that remains to be done to fully unleash the ...
Bambang, Widyantoro, Noriaki, Emoto
openaire   +2 more sources

Endothelins and the lung

The International Journal of Biochemistry & Cell Biology, 2000
Since endothelins were discovered by Yanasigawa in 1988 it has been recognised that they may have an important role in lung pathophysiology. Despite their biological importance as vasoconstrictors the physiological role of endothelin has not yet been defined within the lungs. This review explores their role in acute and chronic disease.
M J, Boscoe   +3 more
openaire   +2 more sources

Endothelin antagonists

The Lancet, 1999
The very potent endogenous vasoconstrictor endothelin was discovered in 1988. We know now that there are three isoforms (1, 2, and 3) and two receptor subtypes (A and B). A whole range of peptide and non-peptide antagonists has been developed, some selective for A or B receptors and others with non-selective A/B antagonistic activity.
A, Benigni, G, Remuzzi
openaire   +2 more sources

Endothelins Are Angiogenic

Journal of Cardiovascular Pharmacology, 2000
Endothelins-1 and 3 (ET-1 and 3) were evaluated for angiogenesis in the rat cornea. Bisected 2 mm pellets containing 20-1000 ng of ET-1 or ET-3 in Hydron were placed in corneal micro-pockets. Murine vascular endothelial growth factor (VEGF) and human interleukin-8 (IL-8) were positive controls.
E L, Bek, M A, McMillen
openaire   +2 more sources

Endothelin in hypertension

Current Opinion in CARDIOLOGY, 1995
The endothelins, 21-amino-acid peptides produced by the endothelium of blood vessels and many other tissues such as the kidney, brain, endocrine organs, etc., are potent vasoconstrictors, and are also endowed with mitogenic and cell hypertrophic properties.
openaire   +2 more sources

The discovery of endothelins

Cardiovascular Research, 1998
Time for primary review 30 days It is generally accepted that the vascular endothelium is not a simple barrier between the blood stream and vascular bed. It has many functions in the regulation of vascular function that are mediated by various factors released from the endothelium which act on itself or other vascular cells in autocrine and paracrine ...
openaire   +2 more sources

Endothelin and endothelin antagonists in hypertension

Journal of Hypertension, 1998
The endothelins (ET) are potent 21-amino-acid vasoconstrictor peptides produced in many different tissues, particularly in the endothelium of blood vessels. ET-1 is the main endothelin secreted by the endothelium, and acts in a paracrine or autocrine fashion on blood vessels by interacting with ETA or ETB receptors on smooth muscle to stimulate ...
openaire   +1 more source

Inhibitors of endothelin

Medicinal Research Reviews, 1997
With the advent of the first generation of both selective and nonselective endothelin antagonists being a relatively recent event, the manifold therapeutic potentials of these compounds are only now being explored clinically. Undoubtedly, numerous clinical utilities for these compounds will soon be realized.
M L, Webb, T D, Meek
openaire   +2 more sources

Home - About - Disclaimer - Privacy